Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 47 - per page Next page
Order by
Colostrinin is a proline-rich polypeptide complex produced from colostrum and is under development as a neutraceutical treatment for 'the prevention of cognitive decline' in both humans and animals. More
pH maintenance, Spermicide, Microbicide Lubricant More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Collagen-based biodegradable matrices for localized drug delivery More
AT13387, small molecule inhibitor of HSP90 More
Oral treatment for prostate cancer More
ANYARA, TTS, Tumour Targeted Superantigens. Completed phase I. More
AT9283 is a potent aurora (A and B) kinase inhibitor for the treatment of multiple solid tumour and haematological malignancies IND approved: April 2006 More
Displaying 1..10 of 47 - per page Next page
Order by
Partnering consultation free of charge
Maximizing Pharmaceutical Patent Lifecycles
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us